Brostrom Chronic Lateral Ankle Instability Repairs Augmented With BioBrace®

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMassachusetts General Hospital

About this trial

The purpose of this investigation is to evaluate pre- and post-operative patient reported outcomes and functional scores after open non-augmented Broström repair or open Broström repair augmented with the BioBrace Implant.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-65 years

Chronic lateral ankle instability (>3 months) confirmed by clinical examination (positive anterior drawer test or talar tilt >10°) and imaging (stress X-ray or MRI).

No prior ankle surgery on the affected limb.

Willingness to follow postoperative visits and rehabilitation protocols and filling out the patient reported outcome measures (PROMs) forms.

Disqualifiers

BMI>40

Significant secondary procedures done at the time of repair, including micro-fracture, or any other treatment of osteochondral lesions of the talus or tibia.

Concomitant deltoid ligament insufficiency.

Any worker's compensation case or any subject with a history of infection of the ankle predating the ankle repair. Current orthopedic issues, not related to the ankle, that prevented the patient from performing the functional tests.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Standard Brostrom Repair

    Procedure/Surgery

    Standard-of-care Brostrom repair for chronic lateral ankle instability

  • Brostrom repair with augmentation

    Device

    Brostrom repair with BioBrace

Treatment groups

75 Participants
are divided into 2 treatment groups
Group A: Standard Brostrom Repair (SBR)Other 1 intervention
Group B: Augmented Brostrom Repair (ABR)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Pain VAS

The pain VAS (Visual Analog Scale) is a unidimensional measure of pain intensity, used to record patients' pain progression, or compare pain severity between patients. It consists of a line marked from 0 to 10, with 0 representing "no pain" at one end and 10 "worst imaginable pain" at the other; patients mark their pain level on the line, which is then measured to provide a numerical score from 0 to 10.

Time frame
From enrollment to the last follow-up at 12 months
2

PROMIS Scale v2.0 - Pain Intensity 3a

The PROMIS Scale v2.0 - Pain Intensity 3a scale utilizes a 3-question questionnaire to assess patients' pain experiences over the previous 7 days. The items include the intensity of pain at its worst, the intensity of pain on average, and the level of pain right now. The items are scored on a scale from "Had no pain" to "Very severe".

Time frame
From enrollment to the last follow-up at 12 months.
3

NIH Toolbox Pain Interference CAT Ages 18 v3.0

The NIH Toolbox Pain Interference CAT Ages 18 v3.0 is a computerized adaptive test that evaluates how much pain has interfered with and affected a person's life and daily activities over the previous 7 days. The questions are generated dynamically based on previous answers. Results are reported as a T-score. A higher T-score indicates a greater degree of pain interference.

Time frame
From enrollment to the last follow-up at 12 months.
4

PROMIS Scale v1.2 - Global Mental 2a

The PROMIS Scale v1.2 - Global Mental 2a is a two-question questionnaire assessing participants' mental health, mood, ability to think, and satisfaction with social activities and relationships. The questions are scored from "Excellent" to "Poor".

Time frame
From enrollment to the last follow-up at 12 months.

Secondary outcomes

1

Return to Activity

Participants will fill out biweekly (2 weeks) surveys assessing their participation in any physical activities or sport, participation in their primary physical activities or sport, how often and how long they participated, their performance in those activities, and their own subjective understanding of why their performance may be different than before their injuries.

Time frame
From baseline until participants report full return to activity or until last follow-up at 12 months.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Massachusetts General Hospital

Lead sponsor

CONMED Corporation

Collaborator